Managing atherosclerotic cardiovascular disease (ASCVD) often involves a combination of
lifestyle modifications and medications aiming to decrease the risk of cardiovascular …

Abstract Purpose of Review Atherosclerotic cardiovascular disease (ASCVD) is a leading
cause of premature death. Lipid disorders, particularly elevated serum low-density …

Position paper of the Polish expert group on the use of pitavastatin in the treatment of lipid
disorders in Poland endorsed by the Polish Lipid Association Journals Advances in Dermatology …

Lipid disorders are the most common (even 70%) and worst monitored cardiovascular risk
factor (only 1/4 of patients in Poland and in CEE countries are on the low-density lipoprotein …

Lipoprotein apheresis (LA) is a therapeutic option for hyperlipoproteinemia (a)(hyper-Lp (a))
and atherosclerotic cardiovascular disease (ASCVD). LA improves blood rheology, reduces …

Atherosclerotic cardiovascular disease is the leading cause of death worldwide, and the
high prevalence of risk factors makes the occurrence of premature acute coronary syndrome …

Lipoprotein (a) is a recognized risk factor for ASCVD. There is still no targeted therapy for Lp
(a), however, drugs such as pelacarsen, olpasiran, zerlasiran, lepodisiran and muvalaplin …

We are in the year of the 20th Anniversary of the Archives of Medical Science (AMS). I
remember when in 2004, just 2 years after my graduation, I approached the largest Polish …

In 1971, Dr Akira Endō (Figure 1A), working at the Sankyo company in Tokyo, speculated
that fungi not only contained antibiotics but also inhibitors of other processes, such as …

Nadciśnienie tętnicze jest najczęstszym czynnikiem ryzyka chorób układu sercowo-
naczyniowego (CVD) na świecie. W ostatnich 30 latach częstość występowania …